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Abstract
Hepatocellular carcinoma (HCC) is the third highest cause of cancer death worldwide. In general, the disease is diagnosed at 
an advanced stage when potentially curative therapies are no longer feasible. For this reason, it is very important to develop 
new therapeutic approaches. Retinoic acid (RA) is a natural derivative of vitamin A that regulates important biological processes 
including cell proliferation and differentiation. In vitro studies have shown that RA is effective in inhibiting growth of HCC cells; 
however, responsiveness to treatment varies among different HCC cell lines. The objective of the present study was to determine 
if the combined use of RA (0.1 µM) and cAMP (1 mM), an important second messenger, improves the responsiveness of HCC 
cells to RA treatment. We evaluated the proliferative behavior of an HCC cell line (HTC) and the expression profile of genes 
related to cancer signaling pathway (ERK and GSK-3β) and liver differentiation [E-cadherin, connexin 26 (Cx26), and connexin 
32 (Cx32)]. RA and cAMP were effective in inhibiting the proliferation of HTC cells independently of combined use. However, 
when a mixture of RA and cAMP was used, the signals concerning the degree of cell differentiation were increased. As dem-
onstrated by Western blot, the treatment increased E-cadherin, Cx26, Cx32 and Ser9-GSK-3β (inactive form) expression while 
the expression of Cx43, Tyr216-GSK-3β (active form) and phosphorylated ERK decreased. Furthermore, telomerase activity 
was inhibited along treatment. Taken together, the results showed that the combined use of RA and cAMP is more effective 
in inducing differentiation of HTC cells.
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Hepatocellular carcinoma (HCC) is a major healthcare 
problem worldwide representing the fifth leading cause 
of cancer mortality and the third most common cause of 
cancer-related deaths (1). The development of HCC is 
frequently associated with chronic viral infection (hepatitis 
B virus or hepatitis C virus); however, frequent exposure 
to toxic agents (alcohol or aflatoxin) can contribute to the 
development of HCC (2).
In general, HCC is diagnosed in advanced stages 
when potentially curative therapies are not feasible. Only 
a minority of HCC are detected at an early enough stage 
for potentially curative therapies, such as surgical resec-
tion, liver transplantation or local ablation therapy. Thus, 
the development of alternative therapeutic approaches to 
HCC remains one of the most challenging areas of cancer 
research.
Retinoic acid (RA) is an active metabolite of vitamin A 
that regulates important biological processes such as cell 
proliferation, cell differentiation and cell death (3). It has 
been reported that RA inhibits the proliferation of malignant 
tumor cells; however, its negative effect on cell growth is 
dose-dependent and cell-specific (4). 
It is well known that RA not only induces growth inhibi-
tion of leukemia cells, but also stimulates their maturation. 
RA has been used as a chemotherapeutic agent in patients 
with acute promyelocytic leukemia (APL) since 1985 (5). 
Since then, the activity of RA on cell proliferation has been 
investigated in tumor cells derived from solid tumors, in-
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cluding HCC (6-8).
Jung et al. (9) carried out an interesting study working 
with 4 different HCC cell lines (HepG2, SNU354, Hep3B, 
and SNU449). They verified that RA inhibited cell growth 
in only two cell lines (HepG2 and SNU354). Curiously, the 
proliferative behavior of Hep3B and SNU449 cells was 
stimulated by treatment with RA. These results clearly show 
that HCC present distinct responsiveness to RA depending 
on their characteristics. 
The combined use of two or more drugs can be advan-
tageous in chemotherapy. Drug dosage would be lower, 
thus decreasing toxicity. Furthermore, a combination of 
drugs may improve treatment responsiveness through 
synergistic effects. 
It was reported that RA induces the maturation of APL 
cells when used at concentrations close to physiological 
levels (1.0 to 10 nM) due to a sustained increase of the 
endogenous level of cAMP (10). cAMP is a second mes-
senger that can act as a pro- or anti-mitotic agent depending 
of both cell type and the physiological state of the cell. The 
antiproliferative activity of cAMP on HCC cells has been 
demonstrated in some studies. Lee et al. (11) showed G1 
synchronization of HepG2 cells due to down-regulation of 
cyclin A expression. In BEL-7402 cells, cAMP induced Akt 
inactivation with consequent inhibition of proliferation (12). 
Using a rat model of HCC, Kovac et al. (13) demonstrated 
that cAMP can inhibit cell mitogenesis. 
The objective of the present study was to investigate 
the effects of the combined use of RA and cAMP on the 
proliferative behavior and phenotype of an HTC cell line 
derived from rat HCC. Our results showed that both RA 
and cAMP inhibit the proliferation of HTC cells. Moreover, 
the period of inhibition was greater in cells that received 
the mixture than in those treated with either RA or cAMP 
alone. Another advantage of the RA and cAMP combina-
tion is the degree of differentiation achieved. HTC cells 
treated with the drug mixture presented a more differenti-
ated phenotype. Thus, the combined use of RA and cAMP 
extended growth inhibition and increased the degree of 
differentiation of HCC cells.
Material and Methods
Cell culture conditions
The rat HCC cell line (HTC) used in this study was 
acquired from the Cell Bank of Rio de Janeiro (14). 
The cultures were maintained in Dulbecco’s modified 
Eagle’s minimum essential medium (DMEM; Sigma, 
USA) supplemented with 5% fetal bovine serum (FBS; 
Cultilab, Brazil). Cells were grown at 37°C in a humidi-
fied incubator containing 5% CO2 and subcultured every 
2 or 3 days.
Drugs and treatment schedule
Stock solutions of 1 mM RA (Sigma) and 100 mM cAMP 
(Sigma) were prepared and diluted in DMEM (supplemented 
with 5% FBS) to a final concentration of 0.1 µM RA and 1 
mM cAMP. Drugs were used alone or in combination and 
were added on the 3rd day after plating. The treatment 
schedule was standardized using BRL3A, a non-tumoral 
cell line that presents great responsiveness to the drugs 
used (Figure 1). HTC cells were treated for 2 days (T0). 
After this period, the medium was replaced with drug-free 
medium and the cultures were tested for recovery at 24 
(T24) and 48 h (T48).
Bromodeoxyuridine (BrdU) incorporation
Cells were cultured on coverslips in 35-mm dishes at 5 
x 103 cells/plate. On the testing days, 100 µM BrdU (Sigma) 
Figure 1. Laser scanning confocal microscopy images of BRL3A 
cells showing the actin filament distribution pattern at T48. The 
morphology of cells is demonstrated by F-actin staining (red) 
and anti-tubulin immunoreaction (green). Retinoic acid (RA) and 
cAMP induced cytoskeleton reorganization and a change in cell 
shape to polyhedric. Note the presence of binucleated cells in the 
images that indicate microtubule networks.
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was added to the medium for 1 h. The cells were fixed in 
ethanol:acetic acid (3:1) for 30 min and the immunofluores-
cence assay was performed as described by Prado et al. 
(15). Mouse anti-BrdU antibody (Sigma) was incubated (1 
h) in a wet chamber at room temperature. After washes in 
Dulbecco’s phosphate-buffered saline (PBSA), the second-
ary antibody (anti-mouse IgG-FITC, Sigma) was incubated 
for 2 h. The nuclei were stained with 10 µg/mL propidium 
iodide and the coverslips were mounted on histological 
slides with Vecta-Shield (Vector Laboratories, USA). The 
analyses were performed using fluorescence microscopy 
(Zeiss, Germany). One thousand cells were counted in each 
sample. Three independent experiments were performed 
and the data are reported as means ± SD. 
Mitotic index
Cells were cultured on coverslips in 35-mm dishes at 
5 x 103 cells/plate. On the indicated days cells were fixed 
in ethanol:acetic acid (3:1) for 30 min at room tempera-
ture and stained by the Feulgen reaction as described by 
Machado-Santelli et al. (16). Metaphase frequency was 
determined in one thousand cells counted in each sample. 
Data are reported as means ± SD for three independent 
experiments.
Cytoskeleton elements: microtubules and F-actin
Cells were cultured on coverslips in 35-mm dishes at 5 
x 103 cells/plate. Cells were fixed with 3.7% formaldehyde 
for 30 min, and the cell membrane was permeabilized with 
0.5% Triton X-100 for 10 min. Cells were incubated overnight 
with mouse monoclonal primary antibodies (anti-α and anti-β 
tubulin diluted in PBSA at 1:200 and 1:100, respectively) in 
a wet chamber at 4°C. A secondary antibody (anti-mouse 
IgG-FITC, Sigma) was added for 2 h and the microfilaments 
were stained with TRITC-phalloidin for 20 min. Coverslips 
were mounted on histological slides with Vecta-Shield (Vec-
tor Laboratories). The analyses were performed using a 
confocal laser scanning microscope (LSM 510, Zeiss). The 
lasers used were argon (488 nm) and helium-neon (543 
nm) connected to an inverted fluorescence microscope 
(Axiovert 100M, Zeiss). Binucleated cells were quantified in 
fluorescent preparations by analyzing 1000 cells per slide. 
Data are reported as means ± SD for three independent 
experiments.
PCR-ELISA telomerase assay
Quantitative determination of telomerase activity was 
performed according to the Telomeric Repeat Amplification 
Protocol using the TeloTAGGG Telomerase PCR ELISAPLUS 
kit (Roche Diagnostic GmbH, Germany). Briefly 2 x 105 
cells were lysed using 2 mL lysis buffer and centrifuged at 
4°C for 30 min at 13,000 rpm. The supernatants of different 
samples were divided into two aliquots before performing 
the assay: one was used as negative control after heat 
inactivation of telomerase at 80°C for 10 min and the other 
was used to evaluate the telomerase-mediated addition 
of the telomeric sequence. The products obtained were 
amplified by PCR. To exclude false-negative results due 
to Taq DNA-polymerase inhibitors eventually present in 
the lysates, a 216-bp long internal standard, present in the 
reaction mixture, was simultaneously amplified. The results 
are reported as relative telomerase activity (RTA), which 
was calculated according to the following formula: RTA = 
[(Abs sample - Abs RNAase-treated sample) / Abs internal 
standard of the sample] / [(Abs control template - Abs lysis 
buffer) / Abs internal standard of the control template] x 100, 
where Abs = absorbance.
Immunoblotting
Cells were cultured in 75-cm2 flasks, washed with cold 
PBSA and scraped into radioimmunoprecipitation assay buf-
fer (150 mM NaCl, 1.0% Nonidet P-40, 0.5% deoxycholate, 
0.1% SDS, and 50 mM Tris, pH 8.0) with both protease and 
phosphatase inhibitors (Sigma). Lysates were centrifuged 
at 10,000 g for 10 min at 4°C. The supernatants were re-
covered, protein was quantified using a bicinchoninic acid 
kit (Pierce Biotechnology Inc., USA) and resuspended in 
Laemmli sample buffer containing 62.5 mM Tris-HCl, pH 6.8, 
2% SDS, 10% glycerol, 5% mercaptoethanol, and 0.001% 
bromophenol blue. A 30-µg protein aliquot was separated by 
SDS-PAGE (10%) and transferred (100 V, 250 mA for 2 h) to 
a polyvinylidene fluoride membrane (Amersham Bioscience, 
USA). The blocking solution (Tris-buffered saline and 0.05% 
Tween 20 = TTBS plus 5% skim milk) was added at 4°C 
for 1 h. The membrane was probed with different antibod-
ies [anti-connexin 43 (Cx43) mouse monoclonal antibody, 
Sigma (1:500); anti-Cx32 mouse monoclonal antibody, 
Sigma (1:300); rabbit polyclonal anti-Cx26 antibody, Sigma 
(1:500); anti-vimentin, Chemicon (1:300, USA); anti-pERK 
(phosphorylated extracellular signal-regulated kinase), 
anti-ERK, anti-Ser9-pGSK-3β (phosphorylated glycogen 
synthase kinase 3 beta), anti-Tyr216-pGSK-3β and anti-
E-cadherin antibodies, Santa Cruz (1:500, USA)]. All blots 
were incubated with the antibodies overnight. After washing 
with TTBS, anti-mouse or anti-rabbit peroxidase-conjugated 
antibodies were added for 2 h at room temperature. The im-
munoreactive bands were visualized with the ECL Western 
blotting detection kit (Amersham Pharmacia) according to 
manufacturer instructions. Anti-α-tubulin antibody was used 
as control to check loading conditions. 
Cell adhesion assay
Adhesion assay was performed on 96-well round-
bottomed plates. Wells were coated with 100 µL laminin-111 
(1 µg/well) overnight at 4°C. Wells were blocked with 3% 
BSA for 30 min at 37°C and rinsed in 0.1% BSA. The cells 
were maintained in a humidified incubator containing 5% 
CO2 at 37°C for 20 min. After attachment, the cells were 
fixed/stained for 10 min with 0.2% (w/v) crystal violet in 
20% (v/v) methanol. After three washes with H2O, cells 
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were dissolved in 10% (w/v) SDS, and the absorbance at 
600 nm was measured. The experiment was performed in 
triplicate and data are reported as means ± SD.
Statistical analysis
The quantitative data are reported as means ± SD. 
ANOVA was performed and the experiments were carried 
out in triplicate. We also applied the Bonferroni multiple 
comparisons test. The Graphpad Prism software (GraphPad 
Software, Inc., USA) was used. 
Results
Standardization of the treatment schedule 
To determine the treatment schedule, we used the 
BRL3A cell line, a lineage established from rat normal liver. 
The assays performed with BRL3A cells showed that RA 
alone was able to induce cell differentiation; however, the 
cell population with a differentiated phenotype was more 
expressive when RA was associated with cAMP. We ob-
served drastic changes in morphology of BRL3A cells as 
well as a significant increase in the frequency of binucleated 
cells, an important indicator of a differentiated phenotype in 
hepatic cells. Thus, we used the same treatment schedule 
for HTC cells, e.g., 48 h of treatment (RA and cAMP used 
in combination or not) followed by 24- and 48-h recovery 
in fresh medium. 
Cell proliferation
HTC cells treated with RA and/or cAMP for 48 h exhibited 
a decrease in cell proliferation, as demonstrated by BrdU 
incorporation and mitotic index (Figure 2). Immediately 
after the treatments (T0) the mitotic indexes were lower 
than control independently of the type of treatment (3.7% 
for the control, 2.5% for RA, 1.84% for cAMP, and 1.78% 
for RA plus cAMP). After 24 h of recovery (T24), the mitotic 
index reached 5.6% in controls as opposed to 0.6, 2.63, 
and 2.16% for cells treated with RA, cAMP and RA plus 
cAMP, respectively. At T48, the cells seemed to recover their 
proliferation capacity, and the mitotic indexes of the treated 
cells were similar to control. The percentage of cells in the 
S-phase at T0 was higher in the control culture (33.76%) 
compared to treated cultures (24.1% in RA, 20% in cAMP, 
and 20% in RA plus cAMP). After a 24-h recovery, BrdU 
indexes were similar for cAMP-treated and control cells 
while the S-phase indexes for RA or cAMP plus RA cells 
remained lower. After a 48-h recovery, the only difference 
was observed in the RA-treated group, with no differences 
among the other three groups.
Cell differentiation
Morphology and adhesion capacity. HTC is a pleomor-
phic cell line, which contains cells with different morphologi-
cal features. This aspect is probably related to differences 
in cell-to-substrate adhesion levels, as indicated by the 
observation of flattened cells that adhere to the substrate 
and rounded cells that grow only partially adhered to the 
substrate (Figure 3A and B). Figure 3 shows different optical 
sections obtained by confocal LSM of cytological prepara-
tions stained with TRITC-phalloidin at T48. In the treated 
cultures, we only observed cells growing tightly adhered 
to the substrate (Figure 3C-H). These cells exhibited actin 
stress fibers that were widely distributed in the cytoplasm 
(Figure 3C, E and G). The pattern of microfilament distribu-
tion in the treated cells was very similar to that observed in 
BRL3A cells, a non-tumoral liver cell line (data not shown). 
Another important aspect of treated cultures was the cel-
lular arrangement. The cells treated with RA and RA plus 
cAMP (Figure 3C,D and G,H) were arranged in a rope-like 
manner. Interestingly, cAMP treatment increased the fre-
quency of binucleated cells (Figure 3E and F). At T48 (the 
time point of immunofluorescent confocal images), 0.3% 
of cells were binucleated in control cultures compared to 
0.5, 1.1, and 1.13% in cultures treated with RA, cAMP and 
RA plus cAMP, respectively.
Figure 2. Cell proliferation behavior of hepatocellular carcinoma 
(HCC) cells as indicated by mitotic index (A) and S-phase cell 
population (B). Data are reported as % total cells. Mitotic indexes 
were significantly lower in cultures treated with retinoic acid (RA), 
cAMP and RA plus cAMP when compared to the control culture 
at T0 and T24. S-phase cell population frequencies were lower 
in all treated cultures compared to control at T0. At T24, cul-
tures treated with RA alone and RA plus cAMP presented lower 
S-phase populations compared to control. At T48, only cultures 
treated with RA presented lower S-phase population than control. 
*P < 0.05, compared to control (Bonferroni test).
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The pattern of microtubule distribution changed ac-
cording to treatment. This was clearly shown in the pro-
jections of Z-stack optical slices from the confocal LSM in 
a single plane image (Figure 4). The microtubules were 
seen more clearly in treated cells than in control cells. 
Both RA and cAMP changed the organization pattern of 
microtubules.
Cell adhesion to the substrate was improved by the treat-
ments. We observed that both RA and cAMP increased the 
adhesion capacity of treated cells to the laminin substrate 
at T0 and T24 (Figure 5). 
Connexin, E-cadherin and vinculin expression
HTC cells preferentially express Cx43, compared to 
low levels or absence of Cx32 or Cx26 expression. This 
pattern of connexin expression did not change at T0, but 
changes in connexin expression profiles were observed 
at T24 and T48. At T24, we detected expression of Cx32 
Figure 3. Laser scanning confocal microscopy images of HTC 
cells showing the pattern of actin filament distribution at T48. Left 
and right panels represent different optical sections on the Z-axis 
obtained during image capture: control cells (A and B), retinoic 
acid (C and D), cAMP (E and F), and retinoic acid plus cAMP (G 
and H). In the control culture shown in B, it is possible to observe 
the presence of rounded cells growing partially adhered to the 
substrate, which were not observed in treated cultures (C-H). 
The treatments induced actin reorganization (actin stress fiber 
formation) and changes in cell shape (C, E and G). Note the 
presence of binucleated cells in cultures treated with cAMP (F). 
Figure 4. Images of HTC cells showing microtubule distribution 
at T48. The microtubule network is more evident in treated cells 
than in control cells, suggesting that retinoic acid (RA) and cAMP 
induced microtubule reorganization. 
Figure 5. The adhesion assay using a laminin substrate showed 
increased cell-to-substrate interaction of treated cells. *P < 0.05 
compared to control (Bonferroni test).
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in cultures treated with cAMP and RA plus cAMP. Also, 
Cx26 was expressed in all treated cells and its expression 
was highest in cells treated with cAMP at T24 (Figure 6). 
At T48, Cx32 expression was up-regulated in cells treated 
with cAMP, RA and RA plus cAMP. At the same time, Cx43 
expression was down-regulated in all groups of treated cells 
(Figure 6). The treatments did not change the pattern of 
vinculin expression; however, at T24 we detected slightly 
increased E-cadherin expression in treated cultures, mainly 
in RA- and cAMP-treated cells. At T48, E-cadherin was 
preferentially expressed in cAMP-treated cells (Figure 6). 
Table 1 summarizes the modifications found in expression 
profiles in HTC cells treated with RA and cAMP.
Telomerase activity
Telomerase activity was another parameter associated 
with both cell proliferation capacity and cell differentiation 
status. The results obtained showed that both cAMP and 
RA can inhibit telomerase activity. cAMP presented strong 
inhibition capacity at T0 while RA was effective in regulating 
telomerase activity negatively at T48. Interestingly, telom-
erase activity was inhibited in cells treated with RA plus 
cAMP from T0 to T48. Figure 7 shows relative telomerase 
activity at the various recovery times. 
Expression of signaling proteins (ERK and GSK-3β)
We investigated the expression profiles of total ERK, 
pERK and GSK-3β phosphorylated at Ser9 or Tyr216. All 
treated cells showed lower phosho-ERK expression lev-
els compared to control cells. However, cells treated with 
cAMP showed decreased pERK expression compared with 
samples treated with RA and RA plus cAMP (Figure 8). We 
investigated the expression of both forms of GSK-3β (active 
and inactive), which corresponds to GSK-3β phosphorylated 
at Tyr216 and Ser9 residues, respectively. Ser9-GSK-3β 
expression levels were lower in control cells than treated 
cells. The cells treated with RA plus cAMP had the highest 
Ser9-GSK-3β expression levels (Figure 8). There were only 
slight changes in Tyr216-GSK-3β expression levels between 
control cells and cells treated with RA plus cAMP (Figure 
8). Changes in the expression profiles of pERK and pGSK 
induced by the treatments are summarized in Table 1.
Discussion
In the present study, we investigated the effects of RA 
and/or cAMP on the proliferative behavior and phenotype 
of HTC cells. We also evaluated a possible synergistic 
effect between RA and cAMP. The treatment schedule 
was designed according to results obtained from BRL3A 
that showed high responsiveness to co-treatment. There-
fore, HTC cells were treated for 48 h with RA or cAMP (in 
combination or not) followed by 24- and 48-h recovery in 
fresh medium. 
HTC cells treated with RA and cAMP exhibited changes 
both in cell morphology and in gene expression profiles 
that were consistent with a differentiated phenotype. It is 
important to note that these events were preferentially ob-
served at the recovery times (T24 and T48), indicating that 
Figure 6. Immunoblot showing the expression pattern of con-
nexins (Cx), E-cadherin and vinculin in treated and control cells. 
α-tubulin was used as the control for sample application. 
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the effects of RA and cAMP on the proliferative behavior 
and phenotype of HTC cells continued after the treatment 
period. This aspect is very important to establish preclini-
cal and clinical protocols that include RA and/or cAMP as 
chemotherapeutic agents.
During the recovery period we observed a decrease 
in Cx43 expression with a concomitant induction of Cx32 
and Cx26 expression. This change in connexin expres-
sion profile occurred independently of the combined use 
of RA and cAMP; however, the highest Cx32 expression 
levels were observed at T48 in cultures treated with RA 
plus cAMP. In the liver, Cx43 is expressed by oval cells 
(hepatic stem-cells), endothelial cells and biliary cells, but 
not by hepatocytes. Cx32 and Cx26 are major connexin 
isoforms expressed by hepatocytes. Cx32 is expressed by 
hepatocytes of the hepatic acini while Cx26 is expressed 
by hepatocytes of the periportal spaces (17). Our results 
are very important because there are almost no data in 
the literature that demonstrate the modulation of connexin 
expression profile as a consequence of RA and/or cAMP 
treatment in hepatic tumor cells. We demonstrated that a 
mixture consisting of RA and cAMP was very effective in 
inducing Cx32 expression. Ara et al. (18) observed an in-
crease of the Cx32 phosphorylated isoform in HepG2 cells 
after treatment with RA and they considered this event to 
be an important aspect of the reversal of the transformed 
phenotype of HepG2 cells. 
In another independent study, Lee et al. (11) observed 
that HepG2 cells treated with cAMP for 3 days presented 
growth arrest as a consequence of both cyclin-dependent 
kinase (cdk) inhibitor up-regulation (p27Kip1, P21 Waf1/
Cip1) and cyclin A down-regulation, although they did not 
report morphological changes associated with a differenti-
ated phenotype.
HepG2 was also used as a model by Alisi et al. (19), 
who detected growth inhibition of HepG2 cells after 7 days 
of treatment with RA. They demonstrated that RA influenced 
the activities of cyclin-cdk complexes involved in the regula-
tion of G1/S transition and S-phase progression, mainly by 
modifying the binding of these complexes to p21 and p27 
inhibitors. Thus, morphological analysis was not performed 
by Lee et al. (11) or by Alisi et al. (19), who worked indepen-
dently to determine the effects of RA or cAMP on hepatic 
tumor cells. The present study shows for the first time the 
results obtained with the separate or concomitant use of 
RA and cAMP on the proliferative behavior and phenotype 
of hepatocarcinoma cells.
Telomerase activity is a hallmark of the immortal pheno-
type and its suppression has been considered an important 
parameter to detect the efficacy of RA in inducing cell differ-
entiation and reversal of transformed phenotype in leukemia 
cells as well as in breast cancer and neuroblastoma cells 
(20-22). We determined that cAMP exerts a strong negative 
effect on telomerase activity, which was observed at T0. 
RA also inhibited telomerase activity; however, this effect 
Figure 7. Relative telomerase activity (RTA) was determined 
using the TeloTAGGG Telomerase PCR ELISAPLUS kit and was 
calculated according to the following formula: RTA = [(Abs sam-
ple - Abs RNAase-treated sample) / Abs internal standard of the 
sample] / [(Abs control template - Abs lysis buffer) / Abs internal 
standard of the control template] x 100, where Abs = absorbance. 
RA = retinoic acid.
Figure 8. Immunoblot showing the expression patterns of signaling 
extracellular signal-regulated kinase (ERK) and glycogen synthase 
kinase 3 beta (GSK-3β) protein at T24. pERK = phosphorylated 
ERK; RA = retinoic acid. Total- ERK was the sample loading control. 
Table 1. Modifications of the expression profiles of HTC cells 
treated with retinoic acid (RA) and cAMP. 
RA cAMP RA + cAMP
Cx43 ↓ ↓ ↓
Cx32 ↑ ↑ ↑
Cx26 ↑ ↑ ↑
E-cadherin Slightly ↑ ↑ ↑
Vinculin No alteration No alteration No alteration
pERK ↓ ↓ ↓
Ser9-GSK-3β ↑ ↑ ↑
Tyr216-GSK-3β Slightly ↓ Slightly ↓ Slightly ↓
The quantitative analysis was performed using ImageJ, a public 
domain program. Cx = connexin; pERK = phosphorylated extra-
cellular signal-regulated kinase; GSK-3β = glycogen synthase 
kinase 3 beta.
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was only seen at T48. Thus, cells treated with the mixture 
(RA plus cAMP) presented inhibition of telomerase activity 
from T0 to T48. The concomitant use of RA and cAMP can 
be useful to improve the effect of treatment, mainly with 
low RA concentrations. In this study, for example, RA was 
used at 0.1 µM. 
Treatment with RA and/or cAMP promoted microfila-
ment reorganization in HTC cells. This event seems to be 
critical to cell shape modification because the treated cells 
became flattened, exhibited polyhedric morphology and 
presented higher adhesion capacity, both cell-to-cell and 
cell-to-substratum. It is possible that the protein complexes 
involved in intercellular contacts and cell polarity were sta-
bilized by cytoskeleton reorganization. We saw important 
up-regulation of E-cadherin expression in cultures treated 
with cAMP, even though we did not observe changes in 
vinculin expression in these cultures. Similar data were 
obtained by Masuda et al. (23), who observed E-cadherin 
up-regulation in hepatocellular carcinoma cells (HCC-T and 
HCC-M) treated with sodium butyrate.
Assays for cell adhesion to a laminin substrate confirmed 
the effect of treatment. After treatment with RA and/or cAMP, 
the cells presented higher adhesion capacity than untreated 
cells. Good adhesive ability may be a relevant and appro-
priate characteristic of well-differentiated cells. Our data 
agree with Massimi and Divirgiliis (24), who demonstrated 
increased adhesiveness of HepG2 cells after treatment with 
RA for 12 days. A similar experimental approach has not 
been previously used with cAMP. Considering that the RAF/
MEK/ERK pathway is constitutively activated in HCC (25-
27), we investigated whether the drugs used in this study had 
some effect on ERK phosphorylation. We observed lower 
pERK expression levels in treated cells compared to control 
cells. This result suggests that the antiproliferative effects of 
RA and cAMP on HTC cells may be due, at least in part, to 
their capacity to negatively regulate ERK phosphorylation. 
Similar results were observed by Kanamori et al. (28), who 
showed cell proliferation inhibition by acriflavine, a synthetic 
retinoid, with concomitant ERK phosphorylation inhibition 
in human HCC cells (HuH7).
In the present study, treatment with cAMP was more 
effective in inhibiting ERK phosphorylation than RA treat-
ment or co-treatment. Thus, we extended our study and also 
investigated the effect of these drugs on GSK-3β, whose 
activity is modulated by several signaling pathways including 
the Wnt, PI-3K/AKT and Ras/MAPK pathways (29). GSK-
3β activity is regulated by site-specific phosphorylation of 
Tyr216/Ser9 residues (30). The active and inactive forms 
are characterized by a phosphorylation pattern at the Tyr216 
and Ser9 residues, respectively. GSK-3β drives oncogenic 
progression either by its inhibition or its activation, depending 
on the tumor (31). In gastrointestinal cancers (pancreatic, 
colorectal and hepatic), lower pSer9-GSK-3β expression 
is commonly observed compared to the active form (32). In 
fact, we observed low pSer9-GSK-3β expression in control 
cells while in treated cells pSer9-GSK-3β expression levels 
were up-regulated. Interestingly, cells treated with RA plus 
cAMP exhibited higher pSer9-GSK-3β expression than cells 
treated with only RA or cAMP. 
The interaction of drugs with the cellular environment 
is extremely complex and requires extensive investigation. 
The exploration of the recovery times permitted us to evalu-
ate in more detail a possible interaction between RA and 
cAMP. For example, if we evaluated independently each 
time we could conclude that there is no synergistic effect 
between RA and cAMP. However, when we analyzed the 
kinetics of the events along the recovery time we noted that 
co-treatment contributed to extending the period during 
which cell growth was inhibited and increased the degree 
of HTC cell differentiation. 
The present study demonstrated that RA and cAMP 
can inhibit cell proliferation and are also effective in induc-
ing differentiation of HTC cells. However, when they are 
used in combination the signals regarding cell proliferation 
inhibition are temporally amplified and the degree of cell 
differentiation is increased. 
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